Jacob Gottlieb’s new business venture is making major healthcare waves in the prescription world
Jacob Gottlieb is often referred to the titan of healthcare investing. He is a highly successful entrepreneur in the financial industry who just added Altium Capital as another business venture. This investment find is based out of New York City and is healthcare-oriented. Its primary focus is on opportunities for investment in the healthcare industry that relates to growth companies. Gottlieb is seeking particular enterprises that offer medical and health treatment advances.
Oragenics, Oramed Pharmaceuticals (ORMP), and the Amarin Corporation (AMRN) are just some of the recent investments of Altium Capital.
Oramed received a 5.6% stake from Altium since their innovative oral treatments from the patients that were diabetic who were receiving their drugs from injectable medications. Oramed has been successful in releasing an insulin capsule that was orally ingestible (ORMD-0801) as well as their (GLP-1) which was a Glucagon-like peptide-1. Oramed has several years of both pharmaceutical and business experience and they take pride in having such an experienced management team on their payroll. World-class scientific experts support the Oramed Corporation.
Amarin headquarters are stationed in Dublin, Ireland. They are a rapidly growing company with offices in Bedminster, New Jersey. Amarin is an innovative pharmaceutical company whose efforts revolve around the development of drugs that improve the cardiovascular system. Their product lines are developing a combination between a lipid science expertise and the benefits of potential therapeutic polyunsaturated fatty acids. In 2012, the FDA approved Aramin’s prescription grade omega 3 fatty acid drug called Vascepa.
In 1996, Oragenics was founded by two doctors based upon the concept of Replacement Therapy. Their focus was to become a front-runner in original antibiotics against contagious diseases as well as oral mucositis treatments that were effective. Replacement Therapy’s goal is to achieve a health-enhancing or therapeutic outcome from substituting a harmful bacteria with a beneficial bacteria.